Ritlecitinib

• CAT Number: I020442
• CAS Number: 1792180-81-4
• Molecular Formula: C₁₅H₁₉N₅O
• Molecular Weight: 285.34
• Purity: ≥95%
• IUPAC Name: 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
• InChI: InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
• InChIKey: CBRJPFGIXUFMTM-WDEREUQCSA-N
• SMILES: C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3

Ritlecitinib (Cat.No:I020442) is a Janus kinase (JAK) inhibitor, particularly targeting JAK1 and JAK3. It has shown potential in preclinical studies for the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis and psoriasis. Further research and clinical trials are ongoing to evaluate its efficacy and safety as a potential therapeutic option.

Reference

[1]. Telliez JB, et al. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol. 2016 Dec 16;11(12):3442-3451.